MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage

The Trump administration has released a formal economic analysis of its most-favored-nation (MFN) drug pricing framework, projecting nearly $600 billion in aggregate savings over 10 years.^1,2 For clinicians, the policy carries direct implications for patient access to high-cost therapeutics, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, biologics, and fertility medications, as well as for prescribing dynamics across payer segments. The projections, while significant, have drawn scrutiny from lawmakers and industry observers who question whether the underlying assumptions will hold.

Policy Rationale and Structural Design

The MFN framework addresses a well-documented market distortion: US net prices for branded drugs run approximately 3 times higher than those in comparable high-income nations, even after rebates. The policy anchors US drug prices to a reference basket comprising 8 high-income countries—Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the UK—using the second-lowest net price among those countries as the MFN benchmark. Critically, the reference price is defined as a net price, inclusive of all manufacturer discounts, rebates, and portfolio-wide clawbacks, to prevent circumvention through inflated list prices with offsetting confidential rebates.

The framework distinguishes between existing drugs and future launches. For newly approved products ("prospective MFN"), manufacturers have committed to launching in the US at prices no greater than the MFN net price, purportedly applied across all payer segments, including commercial insurance. The $529 billion savings projection is derived from this prospective construct, based on reference data from novel drug launches between 2021 and 2025. A more conservative model using only the 2025 cohort, described by the Council of Economic Advisers as more representative of current innovation pipelines, yields a higher estimate of $733 billion. For drugs already on the market, the framework requires MFN pricing to be made available to state Medicaid programs, projected to generate $64.3 billion in combined federal and state savings over a decade, with the biggest anticipated windfall in antipsychotics, antiretrovirals, antineoplastics, and drugs for inflammatory diseases and diabetes.³

Key Uncertainties Clinicians Should Monitor

Despite the headline figures, the exact mechanism for extending MFN savings to commercial markets remains undefined. Existing CMS pilot models cover only Medicare and Medicaid, and the administration has yet to specify how employer-sponsored insurance plans will access discounted rates. The terms of the 17 manufacturer agreements have not been publicly disclosed, making independent verification of projected savings difficult—a point Democratic lawmakers, including Senate Finance Committee Ranking Member Ron Wyden (D, Oregon), have pressed repeatedly, according to an article from Fierce Pharma.

Critically, the full savings picture also depends on the administration's ability to expand agreements well beyond the initial 17 large manufacturers. Mid-sized biopharma companies are already organizing in response; the newly formed Midsized Biotech Alliance of America has raised concerns that companies with 1 or 2 drugs on the market lack the portfolio diversity to absorb revenue pressure that larger manufacturers can offset across broader product lines. Astellas CEO Naoki Okamura confirmed during a recent earnings call that the company had not yet received a formal letter from the government but was proactively preparing for potential MFN expansion, the article stated.

A further structural assumption underpinning the savings model—that the combination of MFN and US trade policy would produce a 30% decrease in US net drug prices over 10 years—carries meaningful uncertainty. AstraZeneca CEO Pascal Soriot indicated during a recent earnings call that the company may avoid launching in certain reference countries if satisfactory reimbursement cannot be obtained. If manufacturers strategically withdraw from benchmark markets to prevent unfavorable reference pricing, the MFN price floor could erode over time.

Implications for GLP-1 Prescribing and Patient Access

GLP-1 receptor agonists, including semaglutide and tirzepatide, represent perhaps the most clinically significant area of near-term impact.^1,2 These agents have demonstrated robust efficacy in weight management, glycemic control, and cardiovascular risk reduction, yet coverage gaps have severely limited access, with only 30% of health plans currently covering GLP-1s for obesity. Under the MFN framework, direct-to-consumer pricing for injectable GLP-1s (Wegovy, Novo Nordisk; Zepbound, Eli Lilly) has been reduced to $350 per month on TrumpRx.gov, down from $1000 to $1350, with initiation doses at $199. Oral GLP-1 initiation doses are available at $149, with higher strengths at $299. Annual savings for uninsured patients are projected to reach $3000 by 2028, according to the report.

The administration also used negotiated GLP-1 price reductions as the basis for a new Medicare coverage expansion. The Medicare GLP-1 Bridge, a Section 402 demonstration beginning July 1, 2026, will provide Part D beneficiaries access to anti-obesity GLP-1 medications outside the standard benefit at a flat $50 monthly co-payment, with a longer-term transition planned under the CMMI BALANCE Model.

Medicaid and High-Cost Biologics

For providers with significant Medicaid patient panels, the framework's most immediate financial impact will be felt in therapeutic classes where Medicaid net prices currently exceed MFN benchmarks by a factor of 2 to 3. The White House projects the greatest Medicaid savings in antipsychotics, antiretrovirals, antineoplastics, anti-inflammatory biologics, and antidiabetics, concentrated in roughly 150 single-source products representing approximately $30 billion in annual net spending. After accounting for an estimated 20% utilization increase attributable to lower patient cost sharing, net Medicaid drug spending on these products is projected to fall by $14.4 billion per year.

Fertility Therapeutics

Reproductive endocrinologists and fertility specialists should note material price reductions in commonly prescribed stimulation protocols. The per-cycle cost of a standard IVF drug regimen, comprising EMD Serono’s follicle-stimulating hormone (Gonal-F), GnRH antagonist (Cetrotide), and hCG trigger (Ovidrel), has decreased from approximately $5187 to $2996, a reduction of $2191 per cycle. For patients of advanced maternal age requiring multiple cycles, cumulative savings per live birth are projected to exceed $6000, with population-level savings for fertility patients estimated at $4.6 billion over 10 years.

Legislative Outlook and Industry Headwinds

The administration is working with Congress to codify the voluntary agreements into statute. That effort faces resistance from an unexpected quarter: in February, a coalition of more than 50 conservative and free-market organizations wrote to members of Congress opposing legislating MFN, arguing it would effectively import foreign price control mechanisms—what they described as "socialist price controls"—into US law.³ Whether codification advances will be a key variable determining the durability of savings projections and the long-term prescribing environment for high-cost branded therapeutics.

Innovation Implications

The White House frames MFN not as a reduction in total pharmaceutical revenue but as a rebalancing of who contributes to global research and development costs.^1,2 The framework is designed to exert upward pricing pressure on reference countries, a dynamic already evident in the recently finalized US-UK pharmaceutical pricing arrangement, which increases UK net drug spending through reduced clawback rates and a higher cost-effectiveness threshold for new product evaluations. Clinicians tracking pipeline drugs should monitor whether foreign market launch sequencing shifts as manufacturers adapt to the new pricing environment and whether selective withdrawal from reference markets blunts the policy's long-term impact.³

References

1. Savings from Most-Favored-Nation drug pricing policy. The White House. May 5, 2026. Accessed May 6, 2026. https://www.whitehouse.gov/research/2026/05/savings-from-most-favored-nation-drug-pricing-policy/
2. The Council of Economic Advisers. Savings from Most-Favored-Nation drug pricing policy. The White House. May 5, 2026. Accessed May 6, 2026. https://www.whitehouse.gov/wp-content/uploads/2026/05/Savings-from-MFN-Drug-Pricing-Policy.pdf
3. Liu A. Touting $529B in savings over 10 years, White House looks to expand MFN deals with pharma. Fierce Pharma. May 6, 2026. Accessed May 6, 2026. https://www.fiercepharma.com/pharma/touting-529b-savings-over-10-years-white-house-looks-expand-mfn-deals-pharma